Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 7/20 | 0.50 |
| ▸ | CA9 | Q16790 | 6/20 | 0.50 |
| ▸ | CA12 | O43570 | 5/20 | 0.50 |
| ▸ | CA1 | P00915 | 5/20 | 0.50 |
| ▸ | PKM | P14618 | 2/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | CA5A | P35218 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | PTGES2 | Q9H7Z7 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6069951 | 0.85 | CA2 (0.46) | CA2CA9CA12CA1PKM | |
| SCHEMBL1791418 | 0.83 | SMN1; SMN2 (0.50) | CA2CA9CA12CA1PKM | |
| SCHEMBL2687430 | 0.81 | GSK3B (0.40) | CA2CA9CA12CA1PKM | |
| SCHEMBL28078917 | 0.81 | TRPV4 (0.47) | CA2CA9CA12CA1PKM | |
| SCHEMBL8528510 | 0.77 | SMN1; SMN2 (0.34) | CA2CA9CA12CA1PKM | |
| SCHEMBL22208964 | 0.76 | ALDH1A1 (0.39) | CA2CA9CA12CA1CA4 | |
| SCHEMBL28699989 | 0.76 | HTR6 (0.65) | PKMHTR6ALDH1A1 | |
| SCHEMBL15018230 | 0.73 | L3MBTL1 (0.59) | SMN1; SMN2ALDH1A1BRD4 | |
| SCHEMBL29581383 | 0.72 | HTR6 (0.60) | CA2CA9CA12CA1PKM | |
| SCHEMBL28279144 | 0.72 | CA2 (0.50) | CA2CA9CA12CA1CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7122565-B2 | Thiadiazoles and oxadiazoles and their use as phosphodiesterase-7 inhibitors | WARNER-LAMBERT LLC (US) | 2006-10-17 | — | — | US | disclosed |
| EP-1326853-B1 | THIADIAZOLES AND OXADIAZOLES AND THEIR USE AS PHOSPHODIESTERASE-7 INHIBITORS | WARNER LAMBERT CO (US) | 2005-09-07 | — | — | EP | disclosed |
| EP-1326853-A1 | NEW THIADIAZOLES AND OXADIAZOLES AND THEIR USE AS PHOSPHODIESTERASE-7 INHIBITORS | Warner-Lambert Company LLC (US) | 2003-07-16 | — | — | EP | disclosed |
| US-20030045557-A1 | Thiadiazoles and oxadiazoles and their use as phosphodiesterase-7 inhibitors | WARNER-LAMBERT COMPANY | 2003-03-06 | — | — | US | disclosed |
| WO-2002028847-A1 | NEW THIADIAZOLES AND OXADIAZOLES AND THEIR USE AS PHOSPHODIESTERASE-7 INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2002-04-11 | — | — | WO | disclosed |
| US-6090825-A | Oxazole derivatives as antagonists of alpha 1C andrenergic receptors | GLAXO WELLCOME INC. (US) | 2000-07-18 | — | — | US | disclosed |
| EP-0793658-A1 | OXAZOLE DERIVATIVES AS ANTAGONISTS OF ALPHA-1C ADRENERGIC RECEPTORS | GLAXO WELLCOME INC. (US) | 1997-09-10 | — | — | EP | disclosed |
| WO-1996016049-A1 | OXAZOLE DERIVATIVES AS ANTAGONISTS OF α-1C ADRENERGIC RECEPTORS | GLAXO WELLCOME INC. (US) | 1996-05-30 | — | — | WO | disclosed |
| US-5100759-A | Color diffusion transfer photography | FUJI PHOTO FILM CO., LTD. (JP) | 1992-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045557-A1 | Thiadiazoles and oxadiazoles and their use as phosphodiesterase-7 inhibitors | PDE3A, PDE3B, PDE7A | CA2 2400/4885CA9 2578/4885CA12 4844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.